Genolution

Genolution FCF per Share

The Free Cash Flow per Share of Genolution (225220.KQ) as of Oct 22, 2026 is -412.36 KRW. In the previous year, Free Cash Flow per Share was -754.26 KRW — a change of -45.33% (higher).

FCF per Share

-412.36KRW

YoY

-45.33%

Last updated:

Free Cash Flow per Share of Genolution is 2025 -412.36 KRW. Free Cash Flow per Share of Genolution was 2024 -754.26 KRW. It decreases by -45.33% higher compared to the previous year.

The Genolution FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-436.73 KRW
Jan 1, 2019
-536.31 KRW
Jan 1, 2020
3,897.45 KRW
Jan 1, 2021
1,126.83 KRW
Jan 1, 2022
-498.22 KRW
Jan 1, 2023
-444.10 KRW
Jan 1, 2024
-754.26 KRW
Jan 1, 2025
-412.36 KRW
The Genolution FCF per Share history
YEARFCF per ShareYoY
-412.36KRW-45.33%
-754.26KRW+69.84%
-444.10KRW-10.86%
-498.22KRW-144.21%
1,126.83KRW-71.09%
3,897.45KRW-826.72%
-536.31KRW+22.80%
-436.73KRW+1,668.66%
-24.69KRW-63.42%
-67.49KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Free Cash Flow per Share of Genolution is -412.36 KRW in 2025.

Free Cash Flow per Share of Genolution changed from -754.26 KRW to -412.36 KRW, representing a -45.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Genolution since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Genolution

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Genolution